Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

HemoGenyx

HemoGenyx
2013 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
HEMO STOCK SYMBOL
1 INVESTMENTS
$0.03 SHARE PRICE (As of Friday Closing)
Description

Hemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy. Its two distinct products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC.

Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
LON
Primary Office
  • 5 Fleet Place
  • London EC4M 7RD
  • England, United Kingdom
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore HemoGenyx’s full profile, request a free trial.

HemoGenyx Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.02 - $0.05 $9.1M $0.03 264K 361M

HemoGenyx Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 12,717 7,973 10,753
Revenue 0 0 0 0
EBITDA (1,973) (1,963) (3,048) (604)
Net Income (1,989) (1,970) (3,041) (636)
Total Assets 1,966 2,918 3,237 872
Total Debt 1,492 1,488 0 372
Public Fundamental Data provided by Morningstar, Inc. disclaimer

HemoGenyx Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore HemoGenyx‘s full profile, request access.

Request full access to PitchBook

HemoGenyx Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 08-Oct-2017 000000000000000000 000.00 Holding Companies 000000000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

HemoGenyx Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore HemoGenyx‘s full profile, request access.

Request full access to PitchBook

HemoGenyx Executive Team (4)

Name Title Board
Seat
Contact
Info
Vladislav Sandler Ph.D Chief Executive Officer & Co-Founder
Alexis Sandler JD Chief Operating Officer & Co-Founder
Lawrence Pemble Chief Operating Officer
Marc Feldmann Executive Chairman

HemoGenyx Board Members (1)

Name Representing Role Since Contact
Info
Marc Feldmann HemoGenyx Executive Chairman 000 0000